Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
19.75 ^USD	-2.57%		+16.18%	+227.53%

Mar. 26	Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding	CI
Mar. 18	Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index	CI

Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 10, 2021 at 04:45 pm EDT

Longboard Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 5.703 million compared to USD 174,000 a year ago. Net loss was USD 5.699 million compared to USD 174,000 a year ago.

Latest news about Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding	Mar. 25	CI
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating	Jan. 16	MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating	Jan. 12	MT
Longboard Pharmaceuticals Closes $242 Million Public Offering	Jan. 08	MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating	Jan. 08	MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating	Jan. 08	MT
Longboard Pharmaceuticals Prices $210 Million Stock Offering	Jan. 04	MT
Longboard Pharmaceuticals Launching Share Offering	Jan. 02	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment	Jan. 02	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02	MT
Top Midday Gainers	Jan. 02	MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating	Jan. 02	MT
Transcript : Longboard Pharmaceuticals, Inc. - Special Call	Jan. 02
Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies	Jan. 02	CI
Guggenheim Raises Longboard Pharmaceuticals' Price Target to $32 From $16, Keeps Buy Rating	Jan. 02	MT
Wedbush Raises Longboard Pharmaceuticals' PT to $22 From $11, Says PACIFIC Data Readout Provides Best-Case Scenario for Bexicaserin (LP352); Keeps Outperform Rating	Jan. 02	MT
Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers	Nov. 29	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Transcript : Longboard Pharmaceuticals, Inc. - Analyst/Investor Day	23-10-11
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Global BMI Index	23-09-18	CI
Longboard Completes Enrollment in Study of LP352 for Treatment of Developmental, Epileptic Encephalopathies	23-08-23	MT

Chart Longboard Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.75 USD

Average target price

42.57 USD

Spread / Average Target

+115.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LONGBOARD PHARMACEUTICALS, INC.	+227.53%	768M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs